ArticleScientific reports2020
Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Caregivers' perceptions of fluorescence-guided surgery (FGS) in pediatric oncology: a questionnaire-based study.Pediatric surgery international · 2026Article
- A Scoping Review on Fluorescence-Guided Surgery in Paediatric Renal Tumours: Current Perspectives and Future Plans.Cancers · 2026Review
- Fluorescence-Guided Surgery in Pediatric Oncology: Current Practice and Future Directions.Cancers · 2025Review
- Next-Generation Imaging Techniques for Surgical Guidance in Pediatric Tumors.Annals of surgical oncology · 2025Review
- Detection properties of indium-111 and IRDye800CW for intraoperative molecular imaging use across tissue phantom models.Journal of biomedical optics · 2025Article
- Antibody conjugates in neuroblastoma: a step forward in precision medicine.Frontiers in oncology · 2025Review
- Advancing Neuroblastoma Surgery through the Clinical Integration of Virtual Reality and Indocyanine Green Fluorescence-Guided Imaging: A Case Report.European journal of pediatric surgery reports · 2025Article
- Dual-labeled anti-GD2 targeted probe for intraoperative molecular imaging of neuroblastoma.Journal of translational medicine · 2024Article
- A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery.EMBO molecular medicine · 2024Article
- Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors.Cancers · 2024Review
- Children's Oncology Group's 2023 blueprint for research: Surgery.Pediatric blood & cancer · 2024Article
- Article
- Survival following complete resection of neuroblastoma in novel orthotopic rat xenograft model.Scientific reports · 2023Article
- Identification of Pediatric Tumors Intraoperatively Using Indocyanine Green (ICG).Annals of surgical oncology · 2023Review
- ASO Author Reflections: Identification of Pediatric Tumors Intraoperatively Using Indocyanine Green (ICG).Annals of surgical oncology · 2023Article
- Fluorescent Probes for Imaging in Humans: Where Are We Now?ACS nano · 2023Review
- Enhancing intraoperative tumor delineation with multispectral short-wave infrared fluorescence imaging and machine learning.Journal of biomedical optics · 2023Article
- Article
- Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma.Cancer research · 2023Article
- Evaluating the Development Status of Fluorescence-Guided Surgery (FGS) in Pediatric Surgery Using the Idea, Development, Exploration, Assessment, and Long-Term Study (IDEAL) Framework.Children (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
Abstract
Neuroblastoma resection represents a major challenge in pediatric surgery, because of the high risk of complications. Fluorescence-guided surgery (FGS) could lower this risk by facilitating discrimination of tumor from normal tissue and is gaining momentum in adult oncology. Here, we provide the first molecular-targeted fluorescent agent for FGS in pediatric oncology, by developing and preclinically evaluating a GD2-specific tracer consisting of the immunotherapeutic antibody dinutuximab-beta, recently approved for neuroblastoma treatment, conjugated to near-infrared (NIR) fluorescent dye IRDye800CW. We demonstrated specific binding of anti-GD2-IRDye800CW to human neuroblastoma cells in vitro and in vivo using xenograft mouse models. Furthermore, we defined an optimal dose of 1 nmol, an imaging time window of 4 days after administration and show that neoadjuvant treatment with anti-GD2 immunotherapy does not interfere with fluorescence imaging. Importantly, as we observed universal, yet heterogeneous expression of GD2 on neuroblastoma tissue of a wide range of patients, we implemented a xenograft model of patient-derived neuroblastoma organoids with differential GD2 expression and show that even low GD2 expressing tumors still provide an adequate real-time fluorescence signal. Hence, the imaging advancement presented in this study offers an opportunity for improving surgery and potentially survival of a broad group of children with neuroblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.